Post My Press Release

Free Press Release Distribution

Author: satishs (Page 1 of 6)

Cough Suppressant Drugs Market – To Grow in the Coming Years, New Research explores Factors Responsible

A cough is a most common symptom of various upper and lower respiratory tract infections. It affects a large proportion of the population leading them to seek medical attention. According to the data published by Journal of the Association of Physicians of India in 2016, cough was identified as the sixth most common reason for hospital outpatient department visits. Cough suppressants, also known as antitussives, are medications that help to suppress cough. Some of the examples of cough suppressants are Dextromethorphan, Codeine, Noscapine, Butamirate, Benzonatate, and Pholcodine. Dextromethorphan and Codeine are the most common and widely used cough suppressant in market.

Key players operating in the global cough suppressant drugs market include Perrigo Company plc, Vernalis plc, Tris Pharma Inc., Pfizer Inc., Aytu BioScience, Inc., Acella Pharmaceuticals LLC, Mayne Pharma Inc., Taro Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd, and GlaxoSmithKline plc.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/2427

Market Dynamics

Frequent launch of new cough suppressants in the market by key players is expected to drive the cough suppressant drugs market growth over the forecast period. For instance, in March 2018, Perrigo Company plc. received the FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-release Tablets, 1200 mg/60 mg). Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive.

Various key players in the market are conducting research and are evaluating safety and efficacy of various drugs for the treatment of cough. Such initiatives taken by companies is expected to lead to the development of new cough suppressant drugs.

For instance, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is evaluating the efficacy and safety of benzonatate soft capsules for improving adult cough symptoms, wherein the study is currently (2018) under phase 3 clinical trial.

High prevalence of cough is also expected to be a major factor for rising demand for cough suppressant drugs, which drives the market growth. For instance, according to the data published by the National Center for Biotechnology Information in 2014, cough is the most common reason for visits to primary care physicians globally, accounting for around 8% of all consultations. According to the same source, the annual prevalence of cough in the general population is reported as approximately 10–33% globally.

The global cough suppressant drugs market size was valued at US$ 1100.4 Mn in 2017 and is expected to witness a CAGR of 3.7% during the forecast period (2018 – 2026).

North America is expected to hold dominant position, owing to frequent approvals of new cough suppressant drugs by FDA

North America cough suppressant market is expected to show good growth over the forecast period, owing to frequent approvals to novel drugs by the FDA. For instance, in 2015, Vernalis plc and Tris Pharma Inc. received the U.S. Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension, CIII (DEA Schedule III). Tuzistra XR is a codeine-based extended-release oral suspension for cough-cold treatment.

Click to Read More On Cough Suppressant Drugs Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Wound Care Market 2018: Business Growth Statistics and Key Players Insights Forecast 2026

Wound care market has witnessed various technological advancements and emerged as a standard solution to treat acute and chronic wounds. Conventional measures of wound care management are being rapidly replaced with advanced wound measure products due to the effectiveness of the latter for managing wounds, which enables faster healing. The treatment in advanced wound care includes intervention therapies and use of products such as antimicrobial dressings, collagen products, foam dressings, hydrocolloids, gauze, hydrogels, film dressings and alginate dressings. Various chronic wound conditions such as arterial ulcers, diabetic ulcers and venous ulcers can compromise the body’s restorative capabilities. The unhealed wounds do not only diminish quality of life but also increases the risk of infections and complications. Therefore, wound care is an important part of surgical recovery or disease management and is a growing medical specialty.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/546

The research and development is growing at a faster pace in wound care market. For instance, DEBRA International in 2017 started a clinical research program, wound healing in Epidermolysis Bullosa, to develop the understanding, the causes and consequences of non-healing wounds. Also different research activities were undertaken by World Union of Wound Healing Societies in 2016 for the development of biomaterials to be used on acute and chronic wounds. Other factors favoring the market growth include increase in acute and chronic conditions such as diabetic foot ulcers, venous ulcers and pressure ulcers. According to Centers for Disease Control & Prevention, diabetes affects 23.6 million people or 7.8 percent of the population in the U.S., and one-third of all diabetics suffered from lower extremity wounds in 2016. These wounds increase the likelihood of foot problems and the potential for amputation. The packaging trends of advanced wound care products also adds to the increased demand in home care settings as people are able to use them without much medical assistance. For instance, V.A.C. VERAFLO Dressings by KCI Licensing are provided with sterile barrier by using extruded multilayers of nylon.

Wound care market taxonomy:

On the basis of type of wound,

Acute Wound Care

Chronic Wound Care

On the basis of product type,

Advanced Wound Management Products

Surgical Wound Care Products

Traditional/Basic Wound Care Products

On the basis of end user,

Hospitals

Clinics

Ambulatory Surgical Centers

Home Care settings

Asia Pacific emerging as a key market

By geography, North America dominates the market because of the large patient pool for chronic wounds and rapid adoption of new products. According to the National Center for Health Statistics, over US $13 billion was spent on pressure ulcer management in the U.S.in 2015. Moreover, CDC and National Institutes of Health (NIH) estimated that as of 2015, in the U.S. alone approximately 2.5 million pressure ulcers were cured in medical centers. Further Asia Pacific region is ruling out the market. For instance, in January 2016 a distribution agreement was signed between Avita Medical and INDEE Medical for the distribution of its ReCell device in Japan. Also in 2012, Smith & Nephew launched 23 new wound care products in Asian and Chinese markets. Further in the same year, ConvaTec started some operations in India to up bring novel healthcare technologies and treatment measures in Asian market.

Mergers and Acquisitions strengthening the wound care market:

Some of the key players in wound care market are 3M, Coloplast A/S, Baxter International, Inc., Convatec Healthcare B.S.A.R.L, Derma Sciences, Inc., Ethicon, Inc., Hollister, Inc, Mölnlycke Health Care, Smith & Nephew plc, Covidien PLC, Acelity L.P, Kinetic Concept, Inc, Medline Industries, Inc, Integra Lifesciences Corporation, Organogenesis Inc and MPM Medical, Inc. SCA acquired BSN medical in 2015. In July 2014 Clayton, Dubilier & Rice acquired Healogics, the nation’s largest provider of advanced wound care services with nearly 600 hospital outpatient wound care centers. The acquisition of Healthpoint, Ltd in 2012 provided Smith & Nephew plc with an opportunity to strengthen its position in the market. The acquisition of Covidien, the second largest player in wound care market by Medtronichelped the company to strengthen its product portfolio in wound care. The acquisition of Dermagraft Assets from Shire’s Regenerative Medicine in 2014 by Organogenesis strengthens the position pf the acquirer in the chronic wound care market.

For a proper wound care management a major focus is laid on understanding the characteristics of the wound and assessment depends on following factors:

The size and depth of involvement and the extent of undermining required

The appearance of the wound surface, whether it is necrotic or viable

The amount and characteristics of wound exudate

The condition of the periwound tissues depending on whether they are scarred, pigmented, atrophic and cellulitic.

Click To Read More On Wound Care Market

Rx Medical Food Market Benefit and Volume 2018 with Status and Prospect to 2026

Medical food is a category of products for dietary management or supportive therapy for specific disease or medical conditions such as pulmonary and metabolic disorders. Ingredients used in medical foods must have generally recognized as safe (GRAS) status, which is assigned to naturally found food materials. Medical food is different from nutritional food, dietary supplements, and prescription drugs. Medical food is protein-based, nutrient-based (Omega 3 fatty acids, chelated zinc, and isoflavones), and may contain minerals and vitamins such as folic acid and thiamine. These products are prescribed by physicians or taken under their supervision. The U.S. Food & Drug Administration (FDA) has classified medical foods into four major categories namely, nutritional complete products, nutritionally incomplete products, formulas for metabolic disorders, and oral rehydration solutions. The U.S. FDA separately regulates medical food category under Orphan Drug Act (1988) to ensure safety of populace and curb presence of products falsely claiming to cure medical conditions. Medical food does not require premarket approval, specification as an Investigational New Drug (IND), and individual registration with the FDA. However, they are required to support all their health claims with proper laboratory and clinical studies.

The global Rx medical food market was valued at US$ 14,504.6 million in 2016 and is expected to witness a robust CAGR of 7.0% over the forecast period (2017-2025).

Some major players operating in the Rx medical food market are Abbott Laboratories, Danone, Mead Johnson & Company, LLC, Fresenius Kabi AG, Nestle, Primus Pharmaceuticals, Inc., Targeted Medical Pharma, Enzymotec ltd., AlfaSigma, and Pivotal Therapeutics.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/909

Increasing regulatory support and awareness about medical food among healthcare professionals is expected to fuel market growth

The U.S. FDA amended regulations related to formulation and marketing of medical food in 2013, the category, which was previously ill-defined. The new additions clarified some issues associated with marketing and branding of medical food products. Furthermore, the U.S. FDA also states that medical food does not require prescription, rather requires to be consumed under the supervision of a medical practitioner. Furthermore, the medical food market is expected to gain traction, owing to major investments by players such as Nestlé and Danone in research and development of medical foods along with widening scope of applications such as chronic pain, and personalized medicine. Medical food currently available in the market include Axona (Accera), Limbrel, Deplin, Lofenalac, Ensure, Vasculera, and Vascazen.

North America is expected to hold a dominant position in the Rx medical food market over the forecast period, followed by Europe and Asia-Pacific

North America accounts for the largest share in the Rx medical food market, followed by Europe and Asia-pacific. The regulatory authorities in North America and Europe have clearly defined and distinguished the medical food category. The CRN will provide a common platform for major players in the industry to work together towards the advancement of medical food and to increase awareness about medical food among healthcare practitioners and consumers. Nestlé has set out a US$ 500 Mn budget to support medical food research by 2021, which is expected to boost growth of the Rx medical food market over the forecast period.

Click To Read More On Global Rx Medical Food Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Precise Analysis on Business Overview, Product Scope And Ongoing Endoscopy Device Market Development 2026

Endoscopy devices are minimally-invasive diagnostic medical devices used to assess the internal organs of the body. These devices are used to examine unusual symptoms and to perform surgery. Such as device comprises a flexible tube with an attached camera, which allows the doctor to view potential threats without a large incision. While, therapeutic endoscopy devices are modified with surgical instruments to carry out surgeries such as removal of kidney stones and fibroids. The procedure is associated with minimal post operation complications, thus making it the most preferred and pursued procedure in surgery and diagnostics. These devices include operative devices and visualization systems, which gives direct insight of the organs for efficient treatment, unlike other medical imaging devices.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/442

Increasing prevalence of chronic diseases among the aging population to boost market growth

According to the World Health Organization in 2011, the world’s population aged 60 years and above will double from 11% in 2000 to 22% by 2050. Growing geriatric population, who are more prone to cancer, orthopedic, and ophthalmic gastrointestinal diseases, is expected to boost market growth. Also, endoscopy assures low-risk procedures and are easily covered by health insurance. Additionally, rising prevalence of diseases requiring endoscopy for diagnosis and treatment, rising geriatric population, technological advancements, increasing number of FDA approvals, and high number of reimbursement policies are other factors driving growth of the endoscopy devices market.

The global endoscopy device market is segmented on the basis of product type, applications, end user, and geography.

On the basis of product type, the global endoscopy devices market is segmented into:

Endoscopes

Rigid Endoscopes

Flexible Endoscopes

Capsule Endoscopes

Surgical Endoscopes

Robot-assisted Endoscopes

On the basis of applications, global endoscopy devices market is segmented into:

Gastrointestinal Endoscopy

Gynecology Endoscopy

Urology Endoscopy

Bronchoscopy

Laryngoscopy

Neuroendoscopy

Others

On the basis of end user, global endoscopy devices market is segmented into:

Hospitals

Ambulatory Surgical Centers

Clinics

Others

Development of advanced 3D imaging providing depth perception is expected to boost market growth

Regional segmentation of the global endoscopy equipment market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. According to the World Journal of Gastrointestinal Endoscopy in 2016, 7 million people in the U.S. showed symptoms of Gastroesophageal Reflux Disorder (GERD), the number for which was expected to reach around 9 million by 2025. North America thus holds a dominant position in the global endoscopy equipment market with the increasing prevalence of diseases and increasing number of approved government grants. Europe is likely to witness surging demand as a result of rapidly aging population, increasing obese population, growing incidence of associated diseases, as well as advancements in technology pertaining to the devices. According to the Journal of Neurogastroenterology in 2011, the prevalence of endoscopic reflux esophagitis in East Asia accounted for 6% in 2005, which increased to 15% in 2015.

Robot-assisted endoscopic devices are expected to boost market growth in the future

Key players operating in the global endoscopic devices market include Artherx Inc., Boston Scientific Corporation, Conmed Corporation. Covidien has the largest market for capsule endoscopy due to the increased preference amongst physicians globally. Other vendors include Olympus Corporation, Ethicon, Karl Storz GmbH, Fujifilm Holding Corporation, and Richard Wolf GmbH. Click To Read More On Endoscopy Device Market

Peanut Allergy Vaccine Market In-Depth Analysis with Booming Trends Supporting Growth Till 2026

Allergies are medical conditions caused primarily by hypersensitivity of the immune system to some external stimulus. Allergy may cause anaphylaxis—a medical condition that can cause irritation of the skin, swelling of throat, shortness of breath, and in some cases, death. Allergies are caused by various allergens such as pollen grains, or certain foods such as peanuts. Vaccination is the process of administering antigenic material or a vaccine to stimulate one’s immune system to build up an adaptive immunity to pathogens.

Companies operating in the market in the current scenario are focusing on obtaining approval for their products from the respective regulatory bodies. The major companies operating in the market are Allergy Therapeutics, Zicam, Aravax, Immunomic Therapeutic, Inc., Astellas, and Aimmune.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/121

Food allergy is one of the major forms of allergies. Food allergies can be caused by cow’s milk, eggs, shellfish, and many other foods, including peanuts. However, peanut allergy is very prevalent in the present scenario, especially in children. Therefore, peanut allergy vaccine market is likely to gain significant traction in the near future. Peanut allergy vaccine is administered to patients who are detected with a probability of developing peanut allergy, so as to prevent occurrences of allergy attacks such as anaphylaxis in the future. According to a report published by National Centre for Biotechnology Information, allergy to peanuts as well as tree nuts (TNs) is the principal reason for fatal allergic reactions in the U.S., and the occurrences appear to be rising. In this 11 year follow up research, over 1% (around 3 million) people reported peanut or tree nut allergies and the condition has been on the rise, mainly amongst children. According to a report by Food Allergy Research and Education (FARE), peanuts caused the most number of allergies in the U.S., among all food allergens. Hence, peanut allergy vaccine market has a major potential for growth in this region during the forecast period (2018–2026).

Peanut Allergy Vaccine Market Taxonomy

On the basis of end user, the global peanut allergy vaccines market is classified into:

Hospitals

Medical Practitioners

Government Agencies

Personal Clinics

Others

Government initiative towards creating awareness and regulatory approvals for peanut allergy vaccine is necessary for the growth of the market. Some of the other treatment methods for peanut allergy are oral immunotherapy and epinephrine treatment. However, neither of these treatments has gained significant momentum in the peanut allergy treatment market.

Peanut Allergy Vaccine Market Outlook – Increasing prevalence of peanut allergy and lack of proper treatment

Globally, incidence of peanut allergy is increasing supported by rising birth rate. The risk of peanut allergy is more prevalent in countries such as the U.K., Australia, and the U.S. According to American Academy of Allergy Asthma & Immunology, 30.4% of the children with food allergies suffered from multiple allergy attacks. Peanut allergy is such an epidemic condition in the U.S. that the federal Food Allergen Labeling and Consumer Protection Act (FALCPA) mandated that all packaged food sold in the U.S. that include peanuts as an ingredient have to prominently display the word ‘Peanut’ on the label. The only solution to peanut allergy is restraining a patient from having peanuts/peanuts containing products. Nevertheless, peanut vaccine is capable of curing the ailment from a very young age, without any restriction on food. Click To Reading More On Peanut Allergy Vaccine Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Cannabis Testing Market Is Likely To Grow At The Uppermost CAGR During The Forecast Period 2018-2026

Cannabis testing is done for various purpose such as finding concentration of active ingredient (cannabinoids, terpene), which determines the medical potency of the cannabis. It is also tested for determining various other ingredient in given sample. For instance, to determine the pesticide residue content in the given sample that undermines the purity and efficacy. Cannabis testing also involves determination of contaminants such as fungi and bacteria (mycotoxins), which could causes serious pulmonary infections if administered unchecked.

Key players operating in the cannabis testing market include Shimadzu Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Millipore Sigma, AB SCIEX LLC, Cannabix Technologies, Inc., Waters Corporation, Steep Hill Labs, Inc., CannaSafe Analytics, Accelerated Technology Laboratories, Inc., LabLynx, Inc., SC Laboratories Inc., GenTech Scientific, Pharm Labs, LLC, and Digipath Labs, Inc.

Request For Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/170

Furthermore, cannabis testing comprises determination of trace metals such as cadmium, arsenic, leads and mercury over cannabis plants and products, which could impart adverse effect to human health. Three species of cannabis are present, each has different concentration of active ingredient (cannabinoids and terpene), which leads to risk of cannabis adulteration with cannabis species having lower amount of active ingredient. Therefore in such cases cannabis testing would be beneficial to find the authenticity of given specimen.

Overall cannabis testing process involves sample and column preparation, identification of analyte, determining concentration, and separating the analyte. Various analytical techniques majorly used to test the cannabis are Liquid Chromatography (LC) / High Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), Thin Layer Chromatography (TLC), ELISA kits, and Polymerase Chain Reaction (PCR). Cannabis testing products also involves breathe analyzer and other instruments to check concentration of tetrahydrocannabinol when consumed illegally. Tetrahydrocannabinol is psychoactive ingredient.

The global cannabis testing market size was valued at US$ 926.3 million in 2017, and is expected to witness a CAGR of 13.2% over the forecast period (2018 – 2026).

Legalization of cannabis for medicinal and recreational activity to drive growth of the cannabis testing market

Increasing approval of medicinal cannabis products along with extensive research and development activities in the medical cannabis market are expected to support growth of the cannabis testing market.

Cannabis testing market is projected to witness positive growth during the forecast period, owing to the requirement of desired active ingredient detection and undesired trace elements (mycotoxins and trace metals) before utilizing cannabis product for medicinal and recreational purpose. Increased trend of using cannabis for recreational purpose would be another major impetus for simultaneous rise in cannabis testing market.

Various cannabis manufacturer across globe are focused on introducing the cannabis products to target various disease, which in turn is expected to promote application of cannabis testing instruments, as this products need to be approved from the health regulatory bodies for their efficacy and purity. For instance, in May 2018, the U.S Food and Drug Administration (FDA) approved the medication, called Epidiolex manufactured by GW Pharmaceuticals to treat two rare forms of epilepsy caused by Lennox-Gastaut and Dravet syndromes in patients two years and older.

Companies are launching innovative, precise, and efficient analytical platform for cannabis testing, which is expected to fuel market growth. For instance, Agilent Technologies Inc. in 2017, introduced a high-resolution, accurate gas chromatography mass system named as Agilent 7250 GC/Q-TOF system, which combines gas chromatography and quadrupole time-of-flight mass spectrometry with a Low Energy Electron Ionization source enabling high exploration of unknown chemical samples.

High cost of analytical instruments for testing cannabis is one of the factors restraining growth of the market. Furthermore, there are no standards for various residue and unwanted material in cannabis such as pesticide residue, heavy metal, and mycotoxin, which results into inauthenticity of test results given by different cannabis testing laboratories.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/170

Pediatric Clinical Trials Market Trends, Analysis, Growth, Industry Outlook and Overview up to 2026

Clinical trials are the gold standard and must for generating evidence-based data and knowledge in medicine. Clinical trials conducted on children (between age group of 0 to 18) for research and development of drugs or formation of new drugs are called as pediatric clinical trials. Pharmaceuticals and biotechnological industries and government regulatory bodies are collectively focused on improving research and development for pediatrics population. A new law in the U.S. and Europe was passed as pediatric regulation 2007 that required new adult drugs to be tested for use in children. This in turn is expected to lead to increasing number of pediatric clinical trials in the U.S. and worldwide.

Request For A Sample Copy Of This Research Report: www.coherentmarketinsights.com/insight/request-sample/397

Robust product pipeline, increasing approval of new pediatric drugs and high outsourcing for drug development are major factors driving pediatric clinical trials market growth. According to Pharmaceutical Research and Manufacturers’ Association (PHRMA) data in 2018, over 1,300 industry-sponsored pediatric clinical trials are underway across a variety of therapeutic areas, including diseases where there is significant unmet need such as infectious diseases, neurologic conditions, genetic disorders, and several forms of cancer. Similarly, 5 pediatric drugs received U.S. FDA approvals in 2018 and 4 and 7 in 2017 and 2015, respectively.

Moreover, introduction of new approaches in clinical research and implementation of advanced technology is expected to boost the market growth. Adoption of data analytics and machine learning platforms is expected to help in better management of the data generated during trials, which can play key role in faster drug development.

Key features of the study:

This report provides in-depth analysis of the pediatric clinical trials market, provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the global pediatric clinical trials market based on the following parameters–company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans

Browse more detail information about Pediatric Clinical Trials Market Report at: https://www.coherentmarketinsights.com/ongoing-insight/pediatric-clinical-trials-market-397

Robust product pipeline, increasing approval of new pediatric drugs and high outsourcing for drug are factors driving growth of the market 

Increasing number of drugs under clinical stage of development in order to cater to unmet medical needs for pediatric patient population is expected to boost the market growth. According to Pharmaceutical Research and Manufacturers’ Association (PHRMA) data in 2018, over 1,300 industry-sponsored pediatric clinical trials are underway across a variety of therapeutic areas, including diseases where there is significant unmet need such infectious diseases, neurologic conditions, genetic disorders, and several forms of cancer. Furthermore, robust product pipeline and increasing approval of new pediatric drugs is expected to boost the market growth.

Major players operating in the global pediatric clinical trials market include, Syneos Health Inc., IQVIA Holdings, Inc., Charles River Laboratories International Inc., Covance Inc., ICON plc., Pharmaceutical Product Development, LLC, Genentech (F. Hoffmann-La Roche AG), Pfizer, Inc., Bristol – Myers Squibb, GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Johnson & Johnson, Merck & Co., Inc., Shire plc., and Vertex Pharmaceuticals Inc.

Nutraceutical Excipient Market Segmentation and Analysis by Recent Trends, Development and Growth by Regions to 2018-2026

Nutraceuticals are dietary supplements that assist in the treatment and prevention of diseases and enhance the performance of pharmaceutical and food products. Various food structures and their compositions are formed by using nutraceutical excipients that enhance the bioavailability of nutraceuticals containing therapeutic products. The major scope for this market is in food industry. Increasing investment of domestic manufactures is expected to boost growth of the market for nutraceutical excipients.

Get A Sample Copy Of This Business Report: https://www.coherentmarketinsights.com/insight/request-sample/2417

The Global Nutraceutical Excipients – Market Dynamics

Nutraceutical excipients have improved functionalities that improve manufacturing processes of pharmaceutical dosage forms. Such benefits of nutraceutical excipients are expected to boost growth of the market. Moreover, increasing geriatric population in economies such as India and China is expected to boost growth of the market. According to the Central Intelligence Agency’s report in July 2018, the percentage of geriatric population in India and China is expected to 13.69% and 21.56%, respectively by 2022. Sedentary lifestyle increases risk of chronic diseases such as obesity, which in turn boosts the uptake of nutraceuticals and thereby drives the market growth. According to World Health Organization’s (WHO) 2002 report, around 60% – 80% people worldwide lead a sedentary lifestyle.

The Global Nutraceutical Excipients Market – Regional insights

Asia Pacific is expected to hold dominant position in the global market for nutraceutical excipients, owing to growing pharmaceutical manufacturing. According to The Economist Intelligence Unit Report 2012, key players such as Merck & Co. and other global pharmaceutical companies are focusing on expansion in Asia Pacific to lower their production cost. This in turn is expected to boost growth of the global nutraceutical excipient market in Asia Pacific. North America is expected to account for the second largest market share in the global nutraceutical excipient market due to increasing consumption of nutraceuticals and dietary supplements in the region. According to the Council for Responsible Nutrition (CRN) Survey October 2018, around 75% adults in the U.S. consume dietary supplements and the consumption is expected to significantly increase in the near future. Therefore, these factors and scenarios are expected to boost growth of the global nutraceutical excipient market over the forecast period.

The Global Nutraceutical Excipients Market– Competitive landscape

Key players operating in the market include, DuPont, P&G Chemicals, Eastman Chemical Corporation, Huntsman Corporation, Kerry Group plc, ABF, Roquette Freres, Ingredion, Meggle, Hilmar Ingredients, JRS Pharma, Sensient, Innophos, Cargill, IMCD, Avantor Performance Materials, Zydus Wellness, BASF SE, Lubrizol Corporation, Colorcon Inc., Finar Limited., and Shin-Etsu Chemical Co., Ltd.

Key players in the market are focused on developing new products to enhance their market share. For instance, in March 2018, JRS PHARMA introduced PROSOLV SMCC (Silicified Microcrystalline Cellulose) in Japan.

Global Nutraceutical Excipients Market –Taxonomy

On the basis of functionality, the global nutraceutical excipients market is segmented into: Binders, Fillers & Diluents, Disintegrants, Coating Agents, Flavoring Agents, Lubricants

On the basis of form, the global nutraceutical excipients market is segmented into: Dry, Liquid

On the basis of end product, the global nutraceutical excipients market is segmented into: Probiotics, Prebiotics, Proteins & Amino Acids, Vitamins, Minerals, Omega-3 Fatty Acids

On the basis of region, the global nutraceutical excipients market is segmented into: North America, Europe, Asia Pacific, Latin America, Middle East, Africa.

Click To Read More OnNutraceutical Excipient Market

Page 1 of 6

Powered by WordPress & Theme by Anders Norén